← All trials
NCT04338061
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2020
- Primary completion
- Sep 18, 2023
- Completion date
- Jul 10, 2026
- First posted
- Apr 8, 2020
- Last posted
- Apr 8, 2020
- Enrollment
- 930
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Merck KGaALead sponsor
- Merck SeronoCollaborator
- Merck KGaAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.